"Retreatment" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The therapy of the same disease in a patient, with the same agent or procedure repeated after initial treatment, or with an additional or alternate measure or follow-up. It does not include therapy which requires more than one administration of a therapeutic agent or regimen. Retreatment is often used with reference to a different modality when the original one was inadequate, harmful, or unsuccessful.
| Descriptor ID |
D019233
|
| MeSH Number(s) |
E02.887
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Retreatment".
Below are MeSH descriptors whose meaning is more specific than "Retreatment".
This graph shows the total number of publications written about "Retreatment" by people in this website by year, and whether "Retreatment" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2008 | 0 | 3 | 3 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 4 | 4 |
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 14 | 14 |
| 2017 | 0 | 9 | 9 |
| 2018 | 0 | 7 | 7 |
| 2019 | 0 | 5 | 5 |
| 2020 | 0 | 3 | 3 |
| 2021 | 0 | 5 | 5 |
| 2022 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Retreatment" by people in Profiles.
-
Retreatment or prolonged antiviral therapy in severe acute respiratory syndrome Coronavirus-2 infection among immunocompromised patients during 2022-2023: A nationwide claims-based cohort study in Japan. J Infect Chemother. 2025 Nov; 31(11):102830.
-
Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma. Leuk Lymphoma. 2024 Dec; 65(12):1789-1800.
-
Retreatment of Residual and Recurrent Aneurysms After Embolization With the Woven EndoBridge Device: Multicenter Case Series. Neurosurgery. 2022 05 01; 90(5):569-580.
-
Reintroduction of immunosuppressive medications in pediatric rheumatology patients with histoplasmosis: a case series. Pediatr Rheumatol Online J. 2021 Jun 07; 19(1):84.
-
Evaluation of the Gore TAG thoracic branch endoprosthesis in the treatment of proximal descending thoracic aortic aneurysms. J Vasc Surg. 2021 11; 74(5):1483-1490.e2.
-
A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695). Clin Cancer Res. 2021 05 01; 27(9):2435-2441.
-
Fenestrated-branched endovascular aortic repair is a safe and effective option for octogenarians in treating complex aortic aneurysm compared with nonoctogenarians. J Vasc Surg. 2021 08; 74(2):353-362.e1.
-
Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. J Clin Oncol. 2021 03 01; 39(7):807-821.
-
Feasibility of Coronary Access and Aortic?Valve Reintervention in Low-Risk TAVR Patients. JACC Cardiovasc Interv. 2020 03 23; 13(6):726-735.
-
Outcomes of target vessel endoleaks after fenestrated-branched endovascular aortic repair. J Vasc Surg. 2020 08; 72(2):445-455.